Expert Review of Clinical Pharmacology, 2026, volume 19, issue 5, pages 409-418.
Pacritinib was developed to address an unmet need for patients with myelofibrosis.
A pharmacological profile of pacritinib for the treatment of myelofibrosis.
Pacritinib offers a non‑myelosuppressive therapy for patients with severe thrombocytopenia, with potential early signals of disease‑modifying activity.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
- Population Pharmacokinetics and Exposure‑Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
- SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN
- Current treatments, practical management, and emerging investigational therapies for myelofibrosis